STAT Plus: Trump wants the U.S. to pay as little for drugs as other countries do. These companies have the most at stake

By NICHOLAS FLORKO

RUBY WALLAU FOR STAT

President Trump’s forthcoming proposal to lower the cost of expensive physician-administered drugs will hit Amgen, Genentech, and Regeneron hardest.

READ MORE